Related to FDA Requests More Data from Existing Trials with Protalix’ Gaucher Disease Drug

• Cephalon Gains FDA Nod on REMS for Antiepileptic Gabitril
  
• FDA Clears Allergan’s Botox for Prophylactic Treatment of Chronic Migraine
  
• FDA Clears BI’s Pradaxa for Preventing Stroke in Nonvalvular AF Patients
  
• FDA Asks for More Clinical Data Before Approving Lilly's Type 2 Diabetes Drug
  
• FDA Clears Herceptin-Chemotherapy Combo for Metastatic Her2+ Gastric Cancer
  
• FDA Details Requirements for Approval of Arena and Eisai’s Obesity Therapy Lorcaserin
  
• AutoGenomics Granted FDA Approval for Infiniti CYP2C19 Assay
  
• FDA Sanctions Thermo Fisher Scientific’s MRSA Test for Use with Blood Samples
  
• FDA Gives Sunovion’s Schizophrenia Drug the Go-Ahead
  
• Novartis’ Afinitor Cleared by FDA for Treating SEGA Tumors in Tuberous Sclerosis
  
• Ortho-Clinical Diagnostics Granted FDA Approval for Intact Parathyroid Hormone Assay
  
• FDA Clears Fifth Indication for Lilly's Cymbalta as Treatment for Musculoskeletal Pain
  
• FDA Sanctions Drug for the Reduction of Excess Abdominal Fat in HIV-Infected Patients
  
• FDA Broadens Vyvanse Label to Include Adolescents
  
• FDA Clears Eisai’s Marine Sponge-Derived Drug for Metastatic Breast Cancer
  
• EMA Launches Program to Help Firms with Advanced Therapeutics Negotiate Regulatory Maze
  
• Lilly Pays Acrux $87M on FDA Approval of Testosterone Replacement Therapy
  
• FDA Rubber-Stamps APP Pharma’s Generic Topotecan for Small Cell Lung and Cervical Cancers
  
• Pfizer Scores New Approval for Sutent in Europe
  
• Cubist Gets FDA Go-Ahead for Two-Minute IV Injection of Antibiotic